TrialPath

Find a study

Match me to a study

203 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

150 studies on the map

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease — Banner Alzheimer's Institute, PhoenixStudy of ALTO-300 in MDD — Site 200, PhoenixZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamStudy to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease — Local Institution - 0046, HomewoodPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixA Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease — Banner Alzheimers Institute, PhoenixA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) — Irvine Clinical Research ( Site 1041), IrvinePhase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — ATP Clinical Research Inc., IrvineStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Alabama Neurology Associates, BirminghamA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis — Clinical Site, PhoenixClinical Trial on Agitation in Alzheimer's Dementia — ClinCloud, LLC, MaitlandA Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) — Barrow Neurological Institute, PhoenixSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Esperanza Clinical, MurrietaA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Profound Research, LLC, CarlsbadA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia — Advanced Research Center, Inc, AnaheimOpen-label Extension Study in Participants With Early Alzheimer's Disease — GSK Investigational Site, MaitlandA Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease — Irvine Center for Clinical Research /ID# 277752, IrvineA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years — Boston Clinical Trials Inc - Internal Medicine, BostonClinical Study of SNK01 in Participants With Moderate Alzheimer's Disease — Behavioral Research Specialists, LLC, GlendaleA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) — The Ohio State University (OSU) Wexner Medical Center, ColumbusCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleFerritin and Iron Burden in SAH sIRB — Univesity of Iowa Hospital and Clinics, Iowa CityTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityTesting the Pain Clinical Practice Guideline — Future Care Coldspring, BaltimoreAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — Clinical Site, DoralSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoSenicapoc in Alzheimer's Disease — University of California, Davis Alzheimer's Disease Center, SacramentoEffects of Ublituximab on Motor Functions in Multiple Sclerosis — Georgia State University, AtlantaKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborProbiotic Administration for Adolescent Depression — UCSF, San FranciscoAcceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality — The University of Texas Health Science Center at Houston, HoustonIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkMood Effects of Serotonin Agonists: Depression — University of Chicago, ChicagoGlutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine — Emory University, AtlantaInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonSleep Health in U.S. Marines — San Diego State University, San DiegoNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonLeucine in Midlife Depression — Emory University Hospital, AtlantaFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, Columbus5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonA Digital Intervention for Post-Stroke Depression and Executive Dysfunction — Weill Cornell Medical Center, New YorkA Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression — UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los AngelesPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamCognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Massachusetts General Hospital, BostonA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenJAK Signaling in Depression — Emory University, AtlantaNeurobiology of Suicide — National Institutes of Health Clinical Center, BethesdaRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesInvestigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — National Institutes of Health Clinical Center, BethesdaPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los AngelesNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkMindfulness-based Psilocybin Therapy for PTSD — The Ohio State University Medical Center, ColumbusSynaptic Mechanisms of Continuous Theta Burst Stimulation in Depression — McLean Hospital, BelmontPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraOrexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial — James J. Peters Veterans Affairs Medical Center, The BronxSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattleClemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression — University of Illinois College of Medicine, ChicagoCannabidiol for Reduction of Brain Neuroinflammation — Massachusetts General Hospital, BostonEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontStratified Pharmacological Approaches for Regulating Circuit-Level Effects — Stanford University, Palo AltoCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, BoulderHome-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) — NYU Langone Health, New YorkConfirmatory Efficacy Trial of Attention Bias Modification for Depression — Institute for Mental Health Research, AustinPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsA Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients — Mayo Clinic Florida, JacksonvilleEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaPromoting Active Therapy: Path to Wellness — Kansas State University, ManhattanSodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) — NYU Langone Health, New YorkDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — Collaborative Neuroscience Network, Garden GroveLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine — University of Pennsylvania, PhiladelphiaImaging Depression in Parkinson's Disease — Yale University, New HavenRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesApimostinel + Automated Neurocognitive Training for Depression — Western Psychiatric Institute and Clinic, PittsburghEfficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder — McLean Hospital, BelmontEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoPsilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder — Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New YorkSleep to Reduce Incident Depression Effectively in Peripartum — Henry Ford Medical Center, NoviNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaPsilocybin-Assisted Therapy for Intergenerational Trauma — The Parsons Research Center for Psychedelic Healing, New YorkPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease — Johns Hopkins Center for Psychedelic and Consciousness Research, BaltimoreMindfulness Engaged Neurostimulation for Depression (MEND II) — UC San Diego Health Psychiatry, San DiegoTrial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) — Johns Hopkins School of Medicine, BaltimoreSafety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease — Weill Cornell Medicine Brain Health Imaging Institute, New YorkTranscranial Magnetic Stimulation Treatment for Alzheimer's Disease — Massachusetts General Hospital, BostonHuman Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. — University of Miami Department of Neurology, MiamiCholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition — Vanderbilt University Medical Center Clinical Research Center, NashvilleLongitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease — Columbia University Irving Medical Center, New YorkA Study of AMDX-2011P in Participants With Alzheimer's Disease — Associated Retina Consultants, PhoenixDeep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD) — UCLA TMS Clinical and Research Service, Los AngelesRepurposing Siponimod for Alzheimer's Disease — St. Joseph's Hospital and Medical Center, PhoenixBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonExercise to Improve Brain Health in Older African Americans — Rutgers, The State University of New Jersey - Newark campus, NewarkGlutathione, Brain Metabolism and Inflammation in Alzheimer's Disease — Baylor College of Medicine, HoustonUAB Alzheimer's Disease Center Core Cohort - Imaging Substudy — University of Alabama at Birmingham Medical Center, BirminghamAlzheimer's Tau Platform: Master Protocol — University of California, San Francisco, San FranciscoSleep Trial to Prevent Alzheimer's Disease — Washington University School of Medicine, St LouisAssessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease — Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, BostonHuman Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. — University of Miami Department of Neurology, MiamiDORA and LP in Alzheimer's Disease Biomarkers — Washington University in St. Louis, School of Medicine, St LouisPET Imaging Evaluation of [11C]SY08 — MGH, CharlestownOpen-Label Extension Protocol to SNK01-AD01 Study — Behavioral Research Specialists, LLC, GlendaleAssess Fibrin in Brains With AD/ADRD — Massachusetts General Hospital, BostonImpact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) — University of Texas Southwestern Medical Center, DallasNicotinic Acid for the Treatment of Alzheimer's Disease — IU Health Neuroscience Center, IndianapolisSleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND) — University of Virginia, CharlottesvilleUltralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol — Nuclear Imaging Institute, Englewood18F-mFBG Cardiac Uptake With Lewy Body Dementia — Houston Methodist Neurological Institute, HoustonBumetanide in Patients With Alzheimer's Disease — Stanford University, StanfordLow-Dose Radiotherapy for Alzheimer's Disease — Renaissance Institute of Precision Oncology & Radiosurgery, Winter Park

Showing the 150 nearest — narrow your filters for fewer, closer studies.